SFRP1 is a Possible Candidate for Epigenetic Therapy in Non-small Cell Lung Cancer

Overview

Journal BMC Med Genomics

Publisher Biomed Central

Specialty Genetics

Date 2016 Aug 19

PMID 27534621

Citations 18

Authors

Y-H Taguchi

Mitsuo Iwadate

Hideaki Umeyama

Affiliations

Soon will be listed here.

Abstract

Background: Non-small cell lung cancer (NSCLC) remains a lethal disease despite many proposed treatments. Recent studies have indicated that epigenetic therapy, which targets epigenetic effects, might be a new therapeutic methodology for NSCLC. However, it is not clear which objects (e.g., genes) this treatment specifically targets. Secreted frizzled-related proteins (SFRPs) are promising candidates for epigenetic therapy in many cancers, but there have been no reports of SFRPs targeted by epigenetic therapy for NSCLC.

Methods: This study performed a meta-analysis of reprogrammed NSCLC cell lines instead of the direct examination of epigenetic therapy treatment to identify epigenetic therapy targets. In addition, mRNA expression/promoter methylation profiles were processed by recently proposed principal component analysis based unsupervised feature extraction and categorical regression analysis based feature extraction.

Results: The Wnt/β-catenin signalling pathway was extensively enriched among 32 genes identified by feature extraction. Among the genes identified, SFRP1 was specifically indicated to target β-catenin, and thus might be targeted by epigenetic therapy in NSCLC cell lines. A histone deacetylase inhibitor might reactivate SFRP1 based upon the re-analysis of a public domain data set. Numerical computation validated the binding of SFRP1 to WNT1 to suppress Wnt signalling pathway activation in NSCLC.

Conclusions: The meta-analysis of reprogrammed NSCLC cell lines identified SFRP1 as a promising target of epigenetic therapy for NSCLC.

Citing Articles

Integrated analysis of DNA methylome and transcriptome reveals SFRP1 and LIPG as potential drivers of ovarian cancer metastasis.

Yi J, Wu M, Zheng Z, Zhou Q, Li X, Lu Y J Gynecol Oncol. 2023; 34(6):e71.

PMID: 37417299 PMC: 10627750. DOI: 10.3802/jgo.2023.34.e71.

Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma.

Stubbe B, Larsen A, Madsen P, Krarup H, Pedersen I, Lundbye-Christensen S Front Oncol. 2023; 13:1211292.

PMID: 37333823 PMC: 10272559. DOI: 10.3389/fonc.2023.1211292.

Xprediction: Explainable EGFR-TKIs response prediction based on drug sensitivity specific gene networks.

Park H, Yamaguchi R, Imoto S, Miyano S PLoS One. 2022; 17(5):e0261630.

PMID: 35584089 PMC: 9116684. DOI: 10.1371/journal.pone.0261630.

Prognostic value of epigenomic profiling in lung cancer.

Mishra A, Verma M Transl Cancer Res. 2022; 8(2):350-353.

PMID: 35116766 PMC: 8798437. DOI: 10.21037/tcr.2019.03.29.

PCA-based unsupervised feature extraction for gene expression analysis of COVID-19 patients.

Fujisawa K, Shimo M, Taguchi Y, Ikematsu S, Miyata R Sci Rep. 2021; 11(1):17351.

PMID: 34456333 PMC: 8403676. DOI: 10.1038/s41598-021-95698-w.

References

Momparler R . Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2'-deoxycytidine). Front Oncol. 2013; 3:188. PMC: 3725836. DOI: 10.3389/fonc.2013.00188. View

Umeyama H, Iwadate M, Taguchi Y . TINAGL1 and B3GALNT1 are potential therapy target genes to suppress metastasis in non-small cell lung cancer. BMC Genomics. 2014; 15 Suppl 9:S2. PMC: 4290609. DOI: 10.1186/1471-2164-15-S9-S2. View

Huffman K, Martinez E . Pre-clinical studies of epigenetic therapies targeting histone modifiers in lung cancer. Front Oncol. 2013; 3:235. PMC: 3766830. DOI: 10.3389/fonc.2013.00235. View

Tesei A, Brigliadori G, Carloni S, Fabbri F, Ulivi P, Arienti C . Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity. J Cell Physiol. 2012; 227(10):3389-96. DOI: 10.1002/jcp.24039. View

Guo L, Chen S, Jiang H, Huang J, Jin W, Yao S . The expression of S100P increases and promotes cellular proliferation by increasing nuclear translocation of β-catenin in endometrial cancer. Int J Clin Exp Pathol. 2014; 7(5):2102-12. PMC: 4069912. View

Kovalev R, Stam T, Ibatulin F, Bondarev G, Filatov M . [Possibilities of epigenetic anti-tumor therapy in in-vitro models]. Vopr Onkol. 2013; 58(6):800-7. View

Chen M, Chen C, Wang J, Tsai A, Liou J, Pan S . The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Cell Death Dis. 2013; 4:e810. PMC: 3789188. DOI: 10.1038/cddis.2013.330. View

Surana R, Sikka S, Cai W, Shin E, Warrier S, Tan H . Secreted frizzled related proteins: Implications in cancers. Biochim Biophys Acta. 2013; 1845(1):53-65. DOI: 10.1016/j.bbcan.2013.11.004. View

Yin Y, Katz V, Salah Z, Maoz M, Cohen I, Uziely B . Mammary gland tissue targeted overexpression of human protease-activated receptor 1 reveals a novel link to beta-catenin stabilization. Cancer Res. 2006; 66(10):5224-33. DOI: 10.1158/0008-5472.CAN-05-4234. View

10.

Janda C, Waghray D, Levin A, Thomas C, Garcia K . Structural basis of Wnt recognition by Frizzled. Science. 2012; 337(6090):59-64. PMC: 3577348. DOI: 10.1126/science.1222879. View

11.

Pronk S, Pall S, Schulz R, Larsson P, Bjelkmar P, Apostolov R . GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 2013; 29(7):845-54. PMC: 3605599. DOI: 10.1093/bioinformatics/btt055. View

12.

Zhang Y, Miao Y, Yi J, Geng J, Wang R, Chen L . Transcriptional inactivation of secreted frizzled-related protein 1 by promoter hypermethylation as a potential biomarker for non-small cell lung cancer. Neoplasma. 2010; 57(3):228-33. DOI: 10.4149/neo_2010_03_228. View

13.

Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E . Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci U S A. 2000; 97(23):12776-81. PMC: 18840. DOI: 10.1073/pnas.97.23.12776. View

14.

Gore S . In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?. Leuk Res. 2009; 33 Suppl 2:S2-6. PMC: 10916704. DOI: 10.1016/S0145-2126(09)70226-7. View

15.

Nakazato T, Bono H, Matsuda H, Takagi T . Gendoo: functional profiling of gene and disease features using MeSH vocabulary. Nucleic Acids Res. 2009; 37(Web Server issue):W166-9. PMC: 2703956. DOI: 10.1093/nar/gkp483. View

16.

Miyanaga A, Gemma A, Noro R, Kataoka K, Matsuda K, Nara M . Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther. 2008; 7(7):1923-30. DOI: 10.1158/1535-7163.MCT-07-2140. View

17.

Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S . EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Cancer Res. 2013; 73(8):2428-34. DOI: 10.1158/0008-5472.CAN-12-3479. View

18.

Bafico A, Gazit A, Pramila T, Finch P, Yaniv A, Aaronson S . Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. J Biol Chem. 1999; 274(23):16180-7. DOI: 10.1074/jbc.274.23.16180. View

19.

Chatr-Aryamontri A, Breitkreutz B, Oughtred R, Boucher L, Heinicke S, Chen D . The BioGRID interaction database: 2015 update. Nucleic Acids Res. 2014; 43(Database issue):D470-8. PMC: 4383984. DOI: 10.1093/nar/gku1204. View

20.

Murakami Y, Tanahashi T, Okada R, Toyoda H, Kumada T, Enomoto M . Comparison of hepatocellular carcinoma miRNA expression profiling as evaluated by next generation sequencing and microarray. PLoS One. 2014; 9(9):e106314. PMC: 4162537. DOI: 10.1371/journal.pone.0106314. View